{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:58:35Z","timestamp":1781773115604,"version":"3.54.5"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T00:00:00Z","timestamp":1155081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opsoclonus\u2010myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%\u20133% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long\u2010term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS. Pediatr Blood Cancer 2008;50:679\u2013680. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/pbc.21009","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T17:18:05Z","timestamp":1155143885000},"page":"679-680","source":"Crossref","is-referenced-by-count":15,"title":["Rituximab for treatment of opsoclonus\u2010myoclonus syndrome in neuroblastoma"],"prefix":"10.1002","volume":"50","author":[{"given":"Michael J.","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,9]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1138"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199206000-00002"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197602)37:2<846::AID-CNCR2820370233>3.0.CO;2-L"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(06)80167-8"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.86"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.118200"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70322-5"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70225-1"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199801)30:1<15::AID-MPO6>3.0.CO;2-3"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(00)00227-7"},{"key":"e_1_2_4_13_2","first-page":"499","article-title":"Opsoclonus\u2010myoclonus syndrome: response to plasmapharesis","volume":"41","author":"Sheela SR","year":"2004","journal-title":"Indian Pediatr"},{"key":"e_1_2_4_14_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1542\/peds.2004-0845","article-title":"Immunologic and clinical responses to Rituximab in a child with opsoclonus\u2010myoclonus syndrome","volume":"115","author":"Pranzatelli MR","year":"2005","journal-title":"Pediatrics"},{"key":"e_1_2_4_15_2","article-title":"Response to Rituximab in a child with neuroblastoma and opsoclonus\u2010myoclonus","author":"Bell J","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_4_16_2","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single dose infusion of chimeric anti\u2010CD20 monoclonal antibody (IDEC\u2010C2B8) in patients with recurrent B\u2010cell lymphoma","volume":"84","author":"Maloney DG","year":"1994","journal-title":"Blood"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21009","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:58:47Z","timestamp":1696881527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1002\/pbc.21009"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21009","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,9]]}}}